Axumin (18F-Fluciclovine) PET imaging in men exhibiting no clinically significant cancer on initial negative biopsy of PI-RADS 4 and 5 regions of interest

• Published in: World journal of urology Vol. 40; no. 11; pp. 2765 - 2770
• Main Authors: Becher, Ezequiel, Karls, Shawn, Tong, Angela, Wysock, James S., Taneja, Samir S., Huang, William C., Lepor, Herbert
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2022; Springer Nature B.V
• Subjects: Biopsy; Cancer; Clinical significance; Humans; Image processing; Image-Guided Biopsy - methods; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; Male; Medicine; Medicine & Public Health; Nephrology; Oncology; Original; Original Article; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Prostate cancer; Prostatic Neoplasms - diagnostic imaging; Prostatic Neoplasms - pathology; Retrospective Studies; Urology; Multiparametric magnetic resonance imaging; Prostate cancer; Positron emission tomography; PI-RADS

Purpose The objective of the study was to determine whether Axumin ( 18 F-Fluciclovine) PET/MRI informs the decision to perform an early repeat biopsy of PI-RADS 4/5 region of interest (ROI) exhibiting no clinically significant prostate cancer (csPCa) on initial biopsy. Methods This prospective stud...